Promius Pharma LLC launches new product
Oct 15, 2008 (M2 EQUITYBITES via COMTEX) -- Ceragenix Pharmaceuticals Inc (OTCBB:CGXP), a medical device company focussed on infectious disease and dermatology, said on 14 October that Promius Pharma LLC, a wholly owned subsidiary of Dr. Reddy's Laboratories (DRL) (NYSE: RDY), has launched its first product, EpiCeram Skin Barrier Emulsion, at the 27th Annual Fall Clinical Dermatology Conference. In November 2007, Ceragenix signed an exclusive distribution and supply agreement with DRL for the commercialisation of EpiCeram in the United States. Ceragenix is responsible for the manufacture and supply of the product, while DRL is responsible for the distribution, marketing and sales.
EpiCeram Emulsion is reported to be a novel prescription therapy for the treatment of atopic dermatitis, a skin disease that affects more than 15 million Americans at an estimated cost of USD1bn annually.
(C)2008 M2 COMMUNICATIONS LTD http://www.m2.com